Funding for this research was provided by:
Bristol-Myers Squibb (not applicable)
Received: 14 November 2018
Accepted: 26 March 2019
First Online: 3 April 2019
Ethics approval and consent to participate
: The Early Access Program for nivolumab received the approval by the Ethics Committee of each Italian Center included in the program.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.